Phase I, Non-Randomised, Open-Label, Multi-Centre Dose Escalation Trial Of Bi 764532 (Dll3/Cd3 Igg-Like T Cell Engager [Tce]) + Ezabenlimab (Anti-Pd-1 Antibody) In Patients (Pts) With Small Cell Lung Cancer (Sclc) And Other Neuroendocrine Carcinomas (Necs) Expressing Dll3
BI 764532;Ezabenlimab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase I, Non-Randomised, Open-Label, Multi-Centre Dose Escalation Trial Of Bi 764532 (Dll3/Cd3 Igg-Like T Cell Engager [Tce]) + Ezabenlimab (Anti-Pd-1 Antibody) In Patients (Pts) With Small Cell Lung Cancer (Sclc) And Other Neuroendocrine Carcinomas (Necs) Expressing Dll3 ### Output: BI 764532;Ezabenlimab